

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FIRST QUARTER ENDED 31 OCTOBER 2024⁽¹⁾**

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	31.10.2024	31.10.2023	31.10.2024	31.10.2023
	RM'000	RM'000	RM'000	RM'000
Revenue	13,055	14,524	13,055	14,524
Cost of sales	(7,933)	(9,859)	(7,933)	(9,859)
Gross profit	5,122	4,665	5,122	4,665
Other income	633	507	633	507
Marketing expenses	(301)	(273)	(301)	(273)
Administrative and other expenses	(2,999)	(2,222)	(2,999)	(2,222)
Finance costs	(24)	(51)	(24)	(51)
Profit before tax	2,431	2,626	2,431	2,626
Taxation	(606)	(531)	(606)	(531)
Profit for the financial period,	1,825	2,095	1,825	2,095
Other comprehensive income, net of tax	-	-	-	-
Total comprehensive income	1,825	2,095	1,825	2,095
Profit attributable to:				
Owners of the parent	1,845	1,889	1,845	1,889
Non-controlling interests	(20)	206	(20)	206
	1,825	2,095	1,825	2,095
Earnings per share attributable to owners of the parent ("EPS"):				
Basic and diluted ⁽²⁾ (sen)	0.49	0.51	0.49	0.51

Notes:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 OCTOBER 2024⁽¹⁾

	Unaudited as at 31 October 2024 RM'000	Audited as at 31 July 2024 RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	28,645	28,303
Right-of-use assets	4,659	4,689
Deferred tax assets	-	-
Goodwill	287	287
Current assets		
Inventories	14,922	14,569
Trade and other receivables	19,122	20,131
Marketable securities	4,983	9,278
Current tax assets	1,292	1,219
Derivative assets	-	-
Cash and bank balances	9,383	4,232
TOTAL ASSETS	83,293	82,708
EQUITY AND LIABILITIES		
Equity		
Share capital	44,348	44,348
Reserves	29,482	27,636
Equity attributable to owners of the parent	73,830	71,984
Non-controlling interest	783	789
TOTAL EQUITY	74,613	72,773
Non-current liabilities		
Borrowings	203	256
Lease liabilities	-	-
Government grants	2,503	2,503
Deferred tax liabilities	1,160	1,151
Current liabilities		
Trade and other payables	3,933	4,445
Borrowings	477	606
Lease liabilities	5	14
Government grants	399	430
Current tax liabilities	-	530
TOTAL LIABILITIES	8,680	9,935
TOTAL EQUITY AND LIABILITIES	83,293	82,708

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 31 OCTOBER 2024⁽¹⁾ (cont'd)

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Financial Position is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED
31 OCTOBER 2024⁽¹⁾**

	Attributable to owners of the Parent						
	Non-distributable		Distributable		Total	Non- controlling interest	Total equity
	Share capital	Reorganisati on debit reserve	Retained earnings				
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	
Balance as at 1 August 2024	44,348	(6,851)	34,488	71,985	788	72,773	
Profit for the financial year	-	-	1,845	1,845	(20)	1,825	
Other comprehensive income, net of tax	-	-	-	-	-	-	
Total comprehensive income	-	-	1,845	1,845	(20)	1,825	
<u>Transactions with owners</u>							
- Dividend paid	-	-	-	-	(60)	(60)	
- Ordinary shares	-	-	-	-	75	75	
Total transaction with owners	-	-	-	-	15	15	
Balance as at 31 Oct 2024	44,348	(6,851)	36,333	73,830	783	74,613	

Note:

- (1) The basis of preparation of the Unaudited Consolidated Statement of Changes in Equity is disclosed in Note A1 and should be read in conjunction with the Group Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE FIRST QUARTER ENDED 31 OCTOBER 2024⁽¹⁾

	3-month ended 31 October 2024 RM'000	3-month ended 31 October 2023 RM'000
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	2,431	2,626
Adjustments for:		
Depreciation of property, plant and equipment	633	578
Depreciation of right-of-use assets	30	34
Amortisation of government grants	(92)	(92)
Finance costs	24	51
Interest income	(64)	(48)
Distribution income from short-term fund	(54)	(97)
Property, plant and equipment written off	-	3
Realised gain on fair value adjustment on marketable securities	-	-
Unrealised gain on foreign exchange	(288)	(144)
Unrealised gain on fair value adjustment on marketable securities	-	-
Operating profit before changes in working capital	2,620	2,911
Decrease/(Increase) in inventories	(353)	1,331
Increase in trade and other receivables	1,009	(4,695)
Increase in trade and other payables	(525)	1,225
Cash generated from operations	2,751	772
Government grants received	61	-
Interest received	64	48
Tax paid	(1,200)	(566)
Tax refunded	-	169
Net cash from operating activities	1,676	423
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of marketable securities	-	(1,000)
Purchase of property, plant and equipment	(975)	(1,218)
Proceeds from disposal of marketable securities	4,349	2,500
Net cash from investing activities	3,374	282

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FOURTH QUARTER ENDED
31 OCTOBER 2024⁽¹⁾ (Cont'd)**

	3-month ended 31 October 2024	3-month ended 31 October 2023
	RM'000	RM'000
CASH FLOWS FROM FINANCING ACTIVITIES		
Capital contribution of non-controlling interest	75	-
Dividend paid to non-controlling interest	(60)	-
Drawdown of bankers' acceptance	-	-
Repayment of bankers' acceptance	-	-
Repayment of term loans	(182)	(178)
Interest paid	(23)	(51)
Payment of lease liabilities	(10)	(13)
Net cash used in financing activities	(200)	(242)
Net increase/(decrease) in cash and cash equivalents	4,850	463
Effect of foreign exchange rates changes	301	147
Cash and cash equivalents at beginning of financial year	4,232	6,108
Cash and cash equivalents at end of financial period	9,383	6,718

Notes:

* Represent less than RM1,000.

(1) The basis of preparation of the Unaudited Consolidated Statement of Cash Flows is disclosed in Note A1 and should be read in conjunction with the Group's Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

(The remaining of this page is intentionally left blank)

A. NOTES TO THE INTERIM FINANCIAL REPORT

A1. Basis of preparation

The interim financial report of UMediC Group Berhad (“**UMC**” or the “**Company**”) and its subsidiaries (collectively, the “**Group**”) is unaudited and has been prepared in accordance with Malaysian Financial Reporting Standard (“**MFRS**”) 134, Interim Financial Reporting issued by the Malaysian Accounting Standards Board (“**MASB**”) and Paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad (“**Listing Requirements**”).

This interim financial report should be read in conjunction with the Group’s Audited Financial Statements for the financial year ended 31 July 2024 and the accompanying explanatory notes attached to this interim financial report.

A2. Significant Accounting Policies

The significant accounting policies and methods of computation applied in the unaudited condensed financial statements are consistent with those adopted in audited financial statements for the financial year ended 31 July 2024, except for the adoption of the following MFRSs and Amendment to MFRSs and Interpretation.

(a) New MFRSs adopted during the financial period

The Group and the Company adopted the following Standards and Amendments to Standards of the MFRS Framework that were issued by the MASB during the financial periods:

Title	Effective Date
MFRS 17 <i>Insurance Contracts</i>	1 January 2023
Amendment to MFRS 17 <i>Initial Application of MFRS 17 and MFRS 9 - Comparative Information</i>	1 January 2023
Amendments to MFRS 101 <i>Disclosure of Accounting Policies</i>	1 January 2023
Amendments to MFRS 108 <i>Definition of Accounting Estimates</i>	1 January 2023
Amendments to MFRS 112 <i>Deferred Tax related to Assets and Liabilities arising from a Single Transaction</i>	1 January 2023
Amendments to MFRS 112 <i>International Tax Reform - Pillar Two Model Rules</i>	Refer paragraph 98M of MFRS112

Adoption of the above Standards and Amendments to Standards did not have any material effect on the financial performance or position of the Group and of the Company.

(b) New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2024

The following are Standards and Amendments to Standards of the MFRS Framework that have been issued by the MASB but have not been early adopted by the Group and the Company:

Title	Effective Date
Amendment to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
Amendments to MFRS 101 <i>Classification of Liabilities as Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 <i>Non-current Liabilities with Covenants</i>	1 January 2024
Amendments to MFRS 107 <i>Statement of Cash Flows</i> and MFRS 7 <i>Financial Instruments: Disclosure – Supplier Finance Arrangement</i>	1 January 2024
Amendments to MFRS 121 <i>Lack of Exchangeability</i>	1 January 2025
Amendments to MFRS 9 and MFRS 7 <i>Classification and Measurement of Financial Instruments</i>	1 January 2026
Amendments to <i>Annual Improvements to MFRS Accounting Standards – Volume 11</i>	1 January 2026
MFRS 18 <i>Presentation and Disclosure in Financial Statements</i>	1 January 2027
MFRS 19 <i>Subsidiaries without Public Accountability: Disclosures</i>	1 January 2027
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

A2. Significant Accounting Policies (Cont’d)

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

A3. Auditors' Report

There was no qualification on the audited financial statements of the Group for the financial year ended 31 July 2024.

A4. Seasonal or Cyclical Factors

The business operations of the Group were not affected by any seasonal or cyclical trend during the current quarter and financial period under review.

A5. Material Unusual Items

There were no unusual items affecting the assets, liabilities, equity, net income or cash flows of the Group during the current quarter and financial period under review.

A6. Material Changes in Estimates

There were no changes in estimates that have a material effect in the current quarter and financial period under review.

A7. Debt and Equity Securities

There was no issuance, cancellation, repurchase, resale and repayment of debts and equity securities during the current quarter and financial period under review.

A8. Dividend Paid

No dividend was paid during the current quarter.

A9. Segmental Information

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all its products. The Group is also involved in developing, manufacturing and marketing of its medical consumables.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

- (a) Marketing and distribution – marketing and distribution of medical devices as well as the provision of after-sales service; and
- (b) Manufacturing – developing, manufacturing and marketing of medical consumables.

The Group's segmental information for the financial period under review is as follows:

31 October 2024	Manufacturing	Marketing and distribution	Eliminations	Consolidated
	RM'000	RM'000	RM'000	RM'000
Results				
Revenue from external customers	4,616	8,439	-	13,055
Inter-segment revenue	442	-	(442)	-
Total revenue	5,058	8,439	(442)	13,055
Interest income and distribution income from short-term fund	42	76	-	118
Interest expense	(7)	(21)	4	(24)
Net Interest income	35	55	4	94
Segment profit before tax	776	1,803	(148)	2,431

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

A10. Material Events Subsequent to the end of the Quarter

There were no other material events subsequent to the end of the current quarter and financial year under review that have not been reflected in this interim financial report.

A11. Changes in the Composition of the Group

On 10 October 2024, UMC subscribed an additional 675,000 new ordinary shares in Ateria Medika Sdn. Bhd. ("Ateria") at an issue price of RM1.00 per share, for a cash consideration of RM675,000 ("Subscription").

Upon completion of the Subscription, Ateria is now a 90%-owned subsidiary of UMC.

Apart from the above, there were no changes in the composition of the Group during the current quarter and financial year under review.

A12. Contingent Liabilities and Contingent Assets

There were no material contingent liabilities or contingent assets as at the date of this interim financial report.

A13. Material Capital Commitment

Save as disclosed below, as at 31 October 2024, the Group does not have any other material capital commitment:

	RM'000
Capital expenditure in respect of purchase of property, plant and equipment	
- Approved and contracted for	4,714
- Approved but not contracted for	6,843
Total	11,557

A14. Significant Related Party Transactions

There were no significant related party transactions during the current quarter.

A15. Derivative Financial Instruments

Derivatives

As at 31 October 2024, the Group does not have any derivatives financial instruments.

A16. Fair Value of Financial Liabilities

There were no gains or losses arising from fair value changes of the Group's financial liabilities for the current quarter and financial period under review.

B. EXPLANATORY NOTES PURSUANT TO APPENDIX 9B OF THE LISTING REQUIREMENTS

B1. Review of Performance

	Individual Quarter 3-months ended		Cumulative Quarter 3-months ended	
	31 Oct 2024 (RM'000)	31 Oct 2023 (RM'000)	31 Oct 2024 (RM'000)	31 Oct 2023 (RM'000)
Revenue	13,055	14,524	13,055	14,524
Profit before tax ("PBT")	2,431	2,626	2,431	2,626
Profit for the financial period/year	1,825	2,095	1,825	2,095
Profit attributable to owners of the parent	1,845	1,889	1,845	1,889

The Group's revenue decreased by approximately RM1.47 million or 10.11% from approximately RM14.52 million achieved in the corresponding quarter of the previous financial year to approximately RM13.06 million in the current quarter.

The PBT of the Group decreased by approximately RM0.20 million or 7.43% from approximately RM2.63 million in the corresponding quarter of the previous financial year to approximately RM2.43 million in the current quarter.

The decrease in revenue and PBT in the current quarter as compared to the corresponding quarter was contributed by both the marketing and distribution and manufacturing segments. The decrease was mainly due to a lower demand for medical devices and consumables from both public and private hospitals as well as healthcare service providers. The decrease in PBT was mainly due increase in administrative and other expenses, mainly attributable to increase in staff cost and realised loss on foreign exchange.

B2. Comparison with Immediate Preceding Quarter

	Individual Quarter 3-months ended			
	31 Oct 2024 (RM'000)	31 July 2024 (RM'000)	Differences	
			RM'000	%
Revenue	13,055	14,876	(1,821)	(12.24)
PBT	2,431	3,796	(1,365)	(35.96)
Profit for the financial period	1,825	3,038	(1,213)	(39.93)
Profit attributable to owners of the parent	1,845	3,039	(1,194)	(39.29)

The Group's revenue decreased by approximately RM1.82 million or 12.24% from approximately RM14.88 million achieved in the immediate preceding quarter to approximately RM13.01 million in the current quarter. The decrease in revenue was mainly derived from the lower demand for medical devices and consumables from marketing and distribution segment.

Despite the decrease in the Group's revenue, the Group's PBT decreased by approximately RM1.37 million or 35.63% from approximately RM3.80 million achieved in the immediate preceding quarter to approximately RM2.43 million in the current quarter. The decrease was mainly due to the lower GP margin as well as an increase in administrative and other expenses of approximately RM0.69 million as compared to the immediate preceding quarter.

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B3. Prospects

Given the Malaysian government's sustained commitment towards advancing the nation's healthcare standards, UMC remains optimistic about its future growth trajectory driven by key factors such as the increasing demand for healthcare facility upgrades, healthcare tourism as well as the immense need to address facility overcrowding, enabling the Group to further solidify its pivotal role within the ever-evolving healthcare landscape.

More recently, the government allocated RM45.3 billion to Ministry of Health under Budget 2025 which represented a 10.0% increase over the preceding year's RM41.2 billion. This makes it the second largest budget allocation which is a testament of the government's resolute emphasis in delivering quality healthcare, underscoring the growing importance of both the public and private healthcare sectors. Additionally, RM1.35 billion has been earmarked for upgrading and repairing health facilities fostering a supportive environment for growth within Malaysia's healthcare sector which bodes well with the Group's expectations for favourable financial impacts in upcoming periods.

To better bolster its presence within the medical industry, the Group has incorporated a new subsidiary known as Akiteck which was formed on 20 May 2024 with the intent to design, assemble and distribute medical moulting solution products and related parts. Subsequently, Ateria was also formed with the intent to import, export, market and distribute medical devices as well as the provision of after-sales service. These incorporations are in line with the Group's strategic vision of expanding its portfolio and providing its end customers with a broader and more diversified selection of medical devices. By fostering the development of existing and new brands, the Group aims to meet the anticipated growing demand for both medical devices and further enhance its presence in the medical industry.

Barring unforeseen circumstances, the Group maintains confident of its growth trajectory.

B4. Profit Forecast

The Group did not issue any profit estimate, forecast, projection or internal targets in any public document.

B5. Taxation

The Group's taxation together with the comparison between the effective and statutory tax rates for the current quarter and financial period under review are as follows:

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	3-month ended 31 October 2024 RM'000	3-month ended 31 October 2023 RM'000	3-month ended 31 October 2024 RM'000	3-month ended 31 October 2023 RM'000
Income tax				
Current tax expenses based on profit for the financial period	597	512	597	512
Under/(over)provision of tax expense in prior year	-	21	-	21
Deferred tax				
Relating to origination and reversal of temporary differences	9	(2)	9	(2)
Under/(over)provision in prior years	-	-	-	-
Overall tax expenses	606	531	606	531
Effective tax rate (%)	24.93	20.22	24.93	20.22
Statutory tax rate (%)	24.00	24.00	24.00	24.00

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B5. Taxation (Cont'd)

The Group's effective tax rate was at 24.93% for current financial period. The effective tax rate for current financial period was higher than the statutory tax rate of 24.00% mainly due to the expenses not deductible for tax purposes in current year.

B6. Status of Corporate Proposals

There were no corporate proposals announced and not completed as at the date of this interim financial report.

B7. Utilisation of Proceeds from the IPO

The gross proceeds from the IPO amounting to RM31.11 million is expected to be utilised in the following manner:

Details of the use of proceeds	Estimated timeframe for the use of proceeds upon listing ⁽¹⁾	Proposed Utilisation RM'000	Actual Utilisation RM'000	Percentage utilised %	Deviation	
					RM'000	%
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months	3,500	3,334	95.26	-	-
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months	6,800	-	-	-	-
		10,300	3,334	32.37	-	-
Repayment of bank borrowings ⁽²⁾	Within six (6) months	9,000	9,000	100.00	-	-
Working capital	Within thirty-six (36) months	8,662	8,662	100.00	-	-
Estimated listing expenses	Within two (2) months	3,150	3,150	100.00	-	-
Total		31,112	24,146			

Notes:

- (1) From the date of listing of the Company on the ACE Market of Bursa Securities on 26 July 2022.
- (2) Including lease liabilities owing to financial institutions.

(The remaining of this page is intentionally left blank)

UMediC Group Berhad
(Company No. 202101015347) (1415647-D)
(Incorporated in Malaysia under the Companies Act 2016)

B8. Group Borrowings and Debt Securities

The details of the Group's borrowings are as follows:

	3-month ended 31 October 2024 RM'000	Audited as at 31 July 2024 RM'000
Current liabilities		
Term loan	477	606
Bankers' acceptance	-	-
	477	606
Non-current liabilities		
Term loan	203	256
	203	256
Total borrowings	680	862

All the Group's borrowings are denominated in RM, secured and interest-bearing.

B9. Material Litigation

As at the date of this interim financial report, the Group is not engaged in any material litigation or arbitration proceedings, either as plaintiff or defendant, and the Directors are not aware of any proceedings pending or threatened against the Group, which may materially and adversely affect the financial position or business performance of the Group.

B10. Dividend

No dividend has been declared or recommended for the current quarter ended 31 October 2024.

B11. Earnings Per Share

The basic and diluted EPS for the current quarter and financial period are computed as follows:

	3-month ended 31 October 2024	3-month ended 31 October 2023
Profit attributable to the owners of the parent (RM'000)	1,845	1,889
Number of ordinary shares (unit) ('000)	373,910	373,910
Basic EPS ⁽¹⁾ (sen)	0.49	0.51
Diluted EPS ⁽²⁾ (sen)	0.49	0.51

Notes:

- (1) Basic EPS is calculated by dividing the profit attributable to owners of the parent by the number of ordinary shares outstanding during the financial period under review.
- (2) Diluted EPS is equivalent to the basic EPS as there were no potential dilutive securities in issue during the financial period under review.

UMediC Group Berhad
 (Company No. 202101015347) (1415647-D)
 (Incorporated in Malaysia under the Companies Act 2016)
 (The remaining of this page is intentionally left blank)

B.12 Profit Before Tax

Profit before tax is arrived at after charging/(crediting):

	3-month ended 31 October 2024	3-month ended 31 October 2023
	RM'000	RM'000
Depreciation of property, plant and equipment	633	578
Depreciation of right-of-use assets	30	34
Amortisation of government grants	(92)	(92)
Finance costs	24	51
Interest income	(64)	(48)
Distribution income from short-term fund	(54)	(97)
Property, plant and equipment written off	-	3
Realised gain on fair value adjustment on marketable securities	-	-
Unrealised gain on foreign exchange	(288)	(144)
Unrealised gain on fair value adjustment on marketable securities	-	-

Notes:

* Represent less than RM1,000.

Save as disclosed above, the other disclosure items pursuant to Note 16, of Appendix 9B of the Listing Requirements are not applicable.

BY ORDER OF THE BOARD
 4 December 2024